Verastem, Inc. Presents Data At The 2014 San Antonio Breast Cancer Symposium
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced a poster presentation at the 2014 San Antonio Breast Cancer Symposium (SABCS) taking place December 9 - 13, 2014.
"The clinical relevance of cancer stem cells (CSCs) has perhaps been best documented in breast cancer,” said Jonathan Pachter, Ph.D., Verastem Head of Research. “Our new data demonstrate the functional relevance of the effective knock down of cancer stem cells by our FAK inhibitors, VS-6063 and VS-4718, in preclinical models of triple negative breast cancer.
Help employers find you! Check out all the jobs and post your resume.
"The clinical relevance of cancer stem cells (CSCs) has perhaps been best documented in breast cancer,” said Jonathan Pachter, Ph.D., Verastem Head of Research. “Our new data demonstrate the functional relevance of the effective knock down of cancer stem cells by our FAK inhibitors, VS-6063 and VS-4718, in preclinical models of triple negative breast cancer.
Help employers find you! Check out all the jobs and post your resume.